ArticleInternational journal of molecular sciences2025
Effect of Fibroblast Growth Factor-2 on Melanocyte Proliferation in Tissue-Engineered Skin Substitutes.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Burn patients treated with tissue-engineered skin substitutes (TESs) often experience pigmentation irregularities, including hypopigmentation and pigmentation spots. These issues are thought to stem from the reduced presence of melanocytes through dilution during TES manufacturing. To address this, we hypothesized that supplementing epithelial cell cultures-primarily composed of keratinocytes but also containing melanocytes-with Fibroblast Growth Factor-2 (FGF-2), a known promoter of melanocyte proliferation, could enhance melanocyte growth. This would potentially increase their numbers in TESs and improve pigmentation outcomes. Our findings indicate that FGF-2, at an optimal dose of 0.2 nM, effectively maintains melanocyte numbers in 2D cultures and epithelial cell cultures through the first passage. Importantly, this treatment does not interfere with keratinocyte proliferation or differentiation, nor does it affect TES integrity. However, FGF-2 supplementation alone did not increase the proportion of melanocytes in epithelial cultures beyond the first passage or in TESs. In summary, while FGF-2 supports melanocyte growth in culture, its addition alone was insufficient to significantly improve TES pigmentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.